Titre :

Use of pd-1 targeting, macrophage infiltration, and ido pathway activation in sarcomas a phase 2 clinical trial

Auteur(s) :

Toulmonde, Maud [Auteur]
Institut Bergonié [Bordeaux]
Penel, Nicolas [Auteur]
METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694
Adam, Julien [Auteur]
Institut Gustave Roussy [IGR]
Chevreau, Christine [Auteur]
Institut Universitaire du Cancer de Toulouse - Oncopole [IUCT Oncopole - UMR 1037]
Blay, Jean-Yves [Auteur]
Centre Léon Bérard [Lyon]
Le Cesne, Axel [Auteur]
Institut Gustave Roussy [IGR]
Bompas, Emmanuelle [Auteur]
Institut de Cancérologie de l'Ouest [Angers/Nantes] [UNICANCER/ICO]
Piperno-Neumann, Sophie [Auteur]
Institut Curie [Paris]
Cousin, Sophie [Auteur]
Institut Bergonié [Bordeaux]
Grellety, Thomas [Auteur]
Institut Bergonié [Bordeaux]
Ryckewaert, Thomas [Auteur]
Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille] [UNICANCER/Lille]
Bessede, Alban [Auteur]
Ghiringhelli, François [Auteur]
Pulido, Marina [Auteur]
Institut Bergonié [Bordeaux]
Italiano, Antoine [Auteur]
Institut Bergonié [Bordeaux]

Titre de la revue :

JAMA oncology

Nom court de la revue :

JAMA Oncol.

Numéro :

4

Pagination :

93-97

Date de publication :

2018-01

ISSN :

2374-2437

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

There is a strong rationale for treating sarcomas with immunotherapy. To assess the efficacy and safety of programmed cell death protein 1 (PD-1) targeting in combination with metronomic chemotherapy in sarcomas. This ...
Lire la suite >There is a strong rationale for treating sarcomas with immunotherapy. To assess the efficacy and safety of programmed cell death protein 1 (PD-1) targeting in combination with metronomic chemotherapy in sarcomas. This was an open-label, multicenter, phase 2 study of 4 cohorts of patients with advanced soft-tissue sarcoma (STS), including leiomyosarcoma (LMS), undifferentiated pleomorphic sarcoma (UPS), other sarcomas (others), and gastrointestinal stromal tumor (GIST). All patients received 50 mg twice daily cyclophosphamide 1 week on and 1 week off and 200 mg of intravenous pembrolizumab every 3 weeks. Pembrolizumab in combination with metronomic cyclophosphamide. There was a dual primary end point, encompassing both the nonprogression and objective responses at 6 months per Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 for LMS, UPS, and others and 6-month nonprogression for GIST. An objective response rate of 20% and/or a 6-month nonprogression rate of 60% were determined as reasonable objectives for treatment with meaningful effect. Correlative studies of immune biomarkers were planned from patient tumor and plasma samples. Between June 2015 and July 2016, 57 patients were included (median [range] age, 59.5 [18.5-84.0] years; 24 women [42%]); 50 patients were assessable for the efficacy end point. Three patients experienced tumor shrinkage, resulting in a partial response in a single solitary fibrous tumor. The 6-month nonprogression rates were 0%, 0%, 14.3% (95% CI, 1.8%-42.8%) for LMS, UPS, and others, respectively, and 11.1% (95% CI, 2.8%-48.3%) for GIST. The most frequent adverse events were grade 1 or 2 fatigue, diarrhea, and anemia. The only patient who experienced partial response was the only one with strong programmed cell death 1 ligand 1-positive staining in immune cell. Strong infiltration by macrophage expressing the inhibitory enzyme indoleamine 2,3-dioxygenase 1 (IDO1) was observed in the majority of cases. Moreover, a significant increase in the kynurenine to tryptophan ratio was observed in patient plasma samples during the study treatment. We found that PD-1 inhibition has limited activity in selected STS and GIST. This may be explained by an immunosuppressive tumor microenvironment resulting from macrophage infiltration and IDO1 pathway activation. clinicaltrials.gov Identifier: NCT02406781.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

CHU Lille
Université de Lille

Collections :

• METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694

Date de dépôt :

2019-12-09T16:49:54Z
2024-05-30T11:39:03Z